MIRA INFORM REPORT

 

 

Report No. :

341462

Report Date :

18.09.2015

 

IDENTIFICATION DETAILS

 

Name :

MACLEODS PHARMACEUTICALS LIMITED

 

 

Formerly Known As :

MACLEODS PHARMACEUTICALS PRIVATE LIMITED

 

 

Registered Office :

304, 3rd Floor, Atlanta Arcade, Marol Church Road, Andheri (East), Mumbai – 400 059, Maharashtra

Tel. No.:

91-22-67695800

 

 

Country :

India

 

 

Financials (as on) :

31.03.2014

 

 

Date of Incorporation :

05.06.1989

 

 

Com. Reg. No.:

11-052049

 

 

Capital Investment / Paid-up Capital :

Rs.199.607 Million

 

 

CIN No.:

[Company Identification No.]

U24239MH1989PLC052049

 

 

IEC No.:

Not Available

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

MUMM19656A

 

 

PAN No.:

[Permanent Account No.]

AAACM4100C

 

 

Legal Form :

A Closely Held Public Limited Liability Company

 

 

Line of Business :

The Company is engaged in manufacturing and developing business of pharmaceutical and related activities, including research.

 

 

No. of Employees :

Information declined by the management.

 

 

RATING & COMMENTS

 

MIRA’s Rating :

A (67)

 

RATING

STATUS

PROPOSED CREDIT LINE

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

Fairly Large

 

Status :

Good

 

 

Payment Behaviour :

Regular

 

 

Litigation :

Exist

 

 

Comments :

Subject is an old and established company incorporated in the year 1989 having fine track.

 

It is engaged in the business as manufacturing of pharmaceutical products.

 

Available financial indicates company’s strong financial risk profile marked by healthy networth position with negligible debt and decent profit margin of the company.

 

Fundamentals of the company are strong and healthy.

 

The rating also takes into consideration strong operating efficiency of the company and rich experience of its promoters.

 

Trade relations reported as fair. Business is active. Payment are reported as regular and as per commitment.

 

In view of long track record and strong financial base, the company can be considered good for normal business dealing at usual trade terms and conditions.

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

 

EXTERNAL AGENCY RATING

 

Rating Agency Name

CRISIL

Rating

Long term rating = AA

Rating Explanation

High degree of safety and carry very low credit risk.

Date

April 30, 2014

 

 

RBI DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

 

 

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2015.

 

 

INFORMATION DENIED BY

 

Name :

Mr. Vishwas Bhosle

Designation :

Senior General Manager

Contact No.:

91-22-67695800

Date :

16.09.2015

 

 

LOCATIONS

 

Registered Office :

304, 3rd Floor, Atlanta Arcade, Marol Church Road, Andheri (East), Mumbai – 400 059, Maharashtra, India

Tel. No.:

91-22-67695800

Fax No.:

91-22-28266229/ 29256599

E-Mail :

macleods@vsnl.com

investors@macleodspharma.com

exports@macleodspharma.com

customercare@macleodspharma.com

sagarwal@macleodspharma.com

accounts@macleodspharma.com

Website :

http://www.macleodspharma.com 

Location :

Owned

 

 

Head Office:

G-2, Saket Building, M.I.D.C. Shanti Nagar, Next to Onida House, Mahakali Caves Road, Andheri (East), Mumbai – 400093, Maharashtra, India

 

 

Factory 1 :

Village: Theda, Kharuni- Lodimajra, Thehesil- Nalagarh, Baddi Industrial Estate Area, District: Solan, Himachal Pradesh, India

 

 

Factory 2 / Daman- Premier- Unit II :

Plot no. 25-27,  Survey No. 366, Premier Industrial Estate, Kachigam, Daman – 396 320, Daman and Diu, India

 

 

Factory 3 :

Plot No.2209, GIDC Sarigam, District: Valsad, Gujarat, India

 

 

DIRECTORS

 

As on 30.09.2014

 

Name :

Mr. Banwarilal Murildhar Bawri

Designation :

Managing Director

Address :

5, Vinayak Heights, Upper Govind Nagar, Malad (East), Mumbai – 400 097, Maharashtra, India

Date of Birth/Age :

02.04.1953

Qualification :

D. Pharm

Date of Appointment :

01.04.2010

DIN No.:

00017795

 

 

Name :

Mr. Rajendra Murlidhar Agarwal

Designation :

Managing Director

Address :

5, Vinayak Heights, Upper Govind Nagar, Malad (East), Mumbai – 400 097, Maharashtra, India

Date of Birth/Age :

25.02.1959

Qualification :

M.B.B.S.

Date of Appointment :

01.04.2010

DIN No.:

00034224

 

 

Name :

Mr. Girdharilal Murlidhar Bawri

Designation :

Director

Address :

5, Vinayak Heights, Upper Govind Nagar, Malad (East), Mumbai – 400 097, Maharashtra, India

Date of Birth/Age :

03.08.1947

Qualification :

B. Com / D. Pharma

Date of Appointment :

22.05.1990

DIN No.:

00034197

 

Name :

Ruchi Rajendra Agarwal

Designation :

Director

Address :

5/6 Vinayak Heights, Upper Govind Nagar, Malad East, Mumbai - 400097, Maharashtra, India

Date of Appointment :

30.03.2015

DIN No.:

07139918

 

Name :

Mr. Sanjay Rajdev

Designation :

Director

Address :

3505 Type Iii Flats, Sevenhills Hospital, Marol Maroshi Road, Andheri East, Mumbai - 400059, Maharashtra, India

Date of Appointment :

30.03.2015

DIN No.:

07158097

 

Name :

Mr.Ashok Anant Mahashur

Designation :

Director

Address :

A 509, Dhanvantari CHS, Deonar Municipal Colony, Sector 2, Deonar, Mumbai - 400043, Maharashtra, India

Date of Appointment :

30.03.2015

DIN No.:

07158239

 

 

KEY EXECUTIVES

 

Name :

Mrs. Suvarna Dadabhau Gholap

Designation :

Secretary

Address :

103-A, Building No.26, Tilak Nagar, Chembur, Mumbai – 400 089, Maharashtra, India

Date of Birth/Age :

15.07.1982

Date of Appointment :

01.03.2011

PAN No.:

ANJPG7538B

 

 

Name :

Mr. Vishwas Bhosle

Designation :

Senior General Manager

 

 

Name :

Mr. Vinayak Vasudev Shirodkar

Designation :

Chief Financial Officer

Address :

B 401, Windsor, Shiv Vallabh Road, Borivali (East), Mumbai - 400066, Maharashtra, India

Date of Appointment :

01.10.2014

PAN No.:

AAFPS7254R

 


 

MAJOR SHAREHOLDERS

 

As on 30.09.2014

 

Names of Shareholders

No. of Shares

Percentage of Holding

Anju Agarwal

3256200

16.31

Rajendra Murlidhar Agarwal

3084360

15.45

Banwarilal Murildhar Bawri

3022080

15.14

Prateek Agarwal

2518400

12.62

Girdharilal Murlidhar Bawri

2235360

11.20

Ajay Agarwal

2172550

10.88

Vijay Agarwal

2083610

10.44

Sudha Bawri

884080

4.43

Anushree Agarwal

229200

1.15

Ruchi Agarwal

192840

0.97

Taradevi Bawri

162000

0.81

Rajendra Murlidhar Agarwal HUF

120000

0.60

Total

19960680

100.00

 

As on 30.09.2014

 

Equity Share Break up (Percentage of Total Equity)

 

Category

Percentage

Directors or relatives of Directors

100.00

Total

100.00

 


 

BUSINESS DETAILS

 

Line of Business :

The Company is engaged in manufacturing and developing business of pharmaceutical and related activities, including research.

 

 

Products :

Product Description

Item Code No. (ITC Code)

Medicament

30049029

 

 

Brand Names :

Not Available

 

 

Agencies Held :

Not Available

 

 

Exports :

Not Divulged

 

 

Imports :

Not Divulged

 

 

Terms :

 

Selling :

Not Divulged

 

 

Purchasing :

Not Divulged

 

PRODUCTION STATUS = NOT AVAILABLE

 

 

GENERAL INFORMATION

 

Suppliers :

Reference :

Not Divulged

Name of the Person :

Not Divulged

Contact No.:

Not Divulged

Since How Long Known :

Not Divulged

Experience :

Not Divulged

Maximum Limit Dealt :

Not Divulged

 

 

Customers :

Reference :

Not Divulged

Name of the Person :

Not Divulged

Contact No.:

Not Divulged

Since How Long Known :

Not Divulged

Experience :

Not Divulged

Maximum Limit Dealt :

Not Divulged

 

 

No. of Employees :

Information declined by the management.

 

 

Bankers :

Banker Name

ICICI Bank Limited

Branch Address

1st Floor, Ganesh Darshan Building, L.T. Road, Opposite Shri Sagar Hotel, Borivali (West), Mumbai – 400092, Maharashtra, India

Person Name (With Designation)

Not Divulged

Contact Number

Not Divulged

Name of Account Holder

Not Divulged

Account Number

Not Divulged

Account Since (Date/Year of Account Opening)

Not Divulged

Average Balance Maintained (If Possible)

Not Divulged

Credit Facilities Enjoyed (If any)

Not Divulged

Account Operation

Not Divulged

Remarks (If any)

Not Divulged

 

  • Citi Bank N.A., Commercial Banking Group, Bandra Kurla Complex, Mumbai - 400051, Maharashtra, India

 

 

Facilities :

(Rs. In Million)

SECURED LOAN

As on

31.03.2014

As on

31.03.2013

SHORT TERM BORROWING

 

 

Term Loans from banks

76.850

0.000

Working capital loans from banks

764.409

1496.163

Total

841.259

1496.163

 

Auditors :

 

Name :

Bansal Bansal and Company

Chartered Accountants

Address :

120 Building No.6, Mittal Industrial Estate, Mumbai – 400 059, Maharashtra, India

Tel. No.:

91-22-28507815/66923607/28507816

Fax No.:

91-22-28507816

E-Mail :

mail@bansalbansal.com

 

 

Memberships :

Not Available

 

 

Collaborators :

Not Available

 

 

Subsidiaries :

  • East and West Clothing Private Limited
  • Macleods Tashkent, Uzbek
  • Macleods Pharma UK Limited
  • Macleods Pharmaceuticals SA (PTY) Limited
  • Macleods Pharmaceuticals Limited, Peru S.A.C.
  • Macleods Pharmaceuticals Limited. Ukraine
  • Macleods Pharma USA, INC.
  • Macleods Pharma Japan

 

 

Enterprise under Significant Influence of Key management Personnel or their Relatives :

  • Macleods Laboratories Private Limited
  • Oxalis Labs
  • Pharma Centre

 

 

CAPITAL STRUCTURE

 

As on 31.03.2014

 

Authorised Capital:

No. of Shares

Type

Value

Amount

 

 

 

 

25000000

Equity Shares

Rs.10/- each

Rs.250.000 Million

 

Issued, Subscribed & Paid-up Capital:

No. of Shares

Type

Value

Amount

 

 

 

 

19960680

Equity Shares

Rs.10/- each

Rs.199.607 Million

 


 

FINANCIAL DATA

[all figures are in Rupees Million]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

31.03.2014

31.03.2013

31.03.2012

 

 

 

 

I.              EQUITY AND LIABILITIES

 

 

 

(1)Shareholders' Funds

 

 

 

(a) Share Capital

199.607

199.607

199.606

(b) Reserves & Surplus

16486.456

12281.677

8806.163

(c) Money received against share warrants

0.000

0.000

0.000

 

 

 

 

(2) Share Application money pending allotment

0.000

0.000

0.000

Total Shareholders’ Funds (1) + (2)

16686.063

12481.284

9005.769

 

 

 

 

(3) Non-Current Liabilities

 

 

 

(a) long-term borrowings

19.508

19.507

19.507

(b) Deferred tax liabilities (Net)

258.038

198.442

274.074

(c) Other long term liabilities

83.394

100.058

79.450

(d) long-term provisions

113.541

57.444

40.654

Total Non-current Liabilities (3)

474.481

375.451

413.685

 

 

 

 

(4) Current Liabilities

 

 

 

(a) Short term borrowings

847.604

1502.372

1480.123

(b) Trade payables

2607.959

1448.935

1259.888

(c) Other current liabilities

1490.027

1279.089

686.570

(d) Short-term provisions

19.866

7.399

4.694

Total Current Liabilities (4)

4965.456

4237.795

3431.275

 

 

 

 

TOTAL

22126.000

17094.530

12850.729

 

 

 

 

II.          ASSETS

 

 

 

(1) Non-current assets

 

 

 

(a) Fixed Assets

 

 

 

(i) Tangible assets

4235.437

3179.552

2666.021

(ii) Intangible Assets

39.353

7.774

2.279

(iii) Capital work-in-progress

741.700

537.430

123.774

(iv) Intangible assets under development

0.000

0.000

0.000

(b) Non-current Investments

102.779

98.831

99.459

(c) Deferred tax assets (net)

0.000

0.000

0.000

(d)  Long-term Loan and Advances

1054.916

1154.621

1179.668

(e) Other Non-current assets

1781.188

269.068

67.479

Total Non-Current Assets

7955.373

5247.276

4138.68

 

 

 

 

(2) Current assets

 

 

 

(a) Current investments

0.000

0.000

0.000

(b) Inventories

3935.825

3490.927

2450.497

(c) Trade receivables

3438.543

2851.136

2575.356

(d) Cash and cash equivalents

5023.791

4419.823

3080.621

(e) Short-term loans and advances

1159.752

818.555

375.772

(f) Other current assets

612.716

266.813

229.803

Total Current Assets

14170.627

11847.254

8712.049

 

 

 

 

TOTAL

22126.000

17094.530

12850.729

 

 

PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

31.03.2014

31.03.2013

31.03.2012

 

SALES

 

 

 

 

Income

28205.872

23792.521

18253.629

 

Other Income

758.723

467.378

238.649

 

TOTAL

28964.595

24259.899

18492.278

 

 

 

 

 

Less

EXPENSES

 

 

 

 

Cost of Materials Consumed

9727.316

8169.553

6049.578

 

Purchases of Stock-in-Trade

3556.556

2664.303

1857.542

 

Changes in inventories of finished goods, work-in-progress and Stock-in-Trade

(340.086)

(673.178)

98.450

 

Employees benefits expense

3458.118

3149.761

2460.473

 

Other expenses

6397.591

5983.264

4860.368

 

TOTAL

22799.495

19293.703

15326.411

 

 

 

 

 

Less

PROFIT/ (LOSS)  BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION

6165.100

4966.196

3165.867

 

 

 

 

 

Less

FINANCIAL EXPENSES

24.851

68.056

72.873

 

 

 

 

 

 

PROFIT / (LOSS) BEFORE TAX, DEPRECIATION AND AMORTISATION

6140.249

4898.140

3092.994

 

 

 

 

 

Less/ Add

DEPRECIATION/ AMORTISATION

360.235

274.992

227.393

 

 

 

 

 

 

PROFIT/ (LOSS)  BEFORE TAX

5780.014

4623.148

2865.601

 

 

 

 

 

Less

TAX

1341.706

915.647

145.502

 

 

 

 

 

 

PROFIT/ (LOSS)  AFTER TAX 

4438.308

3707.501

2720.099

 

 

 

 

 

 

EARNINGS IN FOREIGN CURRENCY

 

 

 

 

F.O.B. Value of Exports

0.000

5553.250

3376.110

 

Income from Product Development

111.984

76.371

55.740

 

TOTAL

111.984

5629.621

3431.850

 

 

 

 

 

 

IMPORTS

 

 

 

 

Raw Materials

2533.350

2574.731

1908.988

 

Components/Stores/Spares

10.433

10.328

14.790

 

Finished Goods

33.591

18.824

14.099

 

Capital Goods

145.395

89.091

64.668

 

TOTAL

2722.769

 2692.974

2002.545 

 

 

 

 

 

 

Earnings / (Loss) Per Share (Rs.)

222.35

185.74

136.27

 

CURRENT MATURITIES OF LONG TERM DEBT DETAILS

 

PARTICULARS

 

31.03.2014

31.03.2013

31.03.2012

Current Maturities of Long term debt

NA

NA

NA

Cash generated from operations

NA

NA

NA

Net cash flows from (used in) operations

5423.666

3618.178

1639.501

 

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2014

31.03.2013

31.03.2012

Net Profit Margin

(PAT/Sales)

(%)

15.74

15.58

14.90

 

 

 

 

 

Operating Profit Margin

(PBDIT / Sales)

(%)

21.86

20.87

17.34

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

27.16

28.09

22.69

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.35

0.37

0.32

 

 

 

 

 

Debt Equity Ratio

(Total Debt/Networth)

 

0.05

0.12

0.17

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

2.85

2.80

2.54

 

 

 

 

 

FINANCIAL ANALYSIS

[all figures are in Rupees Million]

 

DEBT EQUITY RATIO

 

Particular

31.03.2012

31.03.2013

31.03.2014

 

(Rs. In Million)

(Rs. In Million)

(Rs. In Million)

Share Capital

199.606

199.607

199.607

Reserves & Surplus

8806.163

12281.677

16486.456

Net worth

9005.769

12481.284

16686.063

 

 

 

 

long-term borrowings

19.507

19.507

19.508

Short term borrowings

1480.123

1502.372

847.604

Total borrowings

1499.630

1521.879

867.112

Debt/Equity ratio

0.167

0.122

0.052

 

 

 

YEAR-ON-YEAR GROWTH

 

Year on Year Growth

31.03.2012

31.03.2013

31.03.2014

 

(Rs. In Million)

(Rs. In Million)

(Rs. In Million)

Sales

18253.629

23792.521

28205.872

 

 

30.344

18.549

 

 

 

NET PROFIT MARGIN

 

Net Profit Margin

31.03.2012

31.03.2013

31.03.2014

 

(Rs. In Million)

(Rs. In Million)

(Rs. In Million)

Sales

18253.629

23792.521

28205.872

Profit

2720.099

3707.501

4438.308

 

14.90%

15.58%

15.74%

 

 

 

 

 

LOCAL AGENCY FURTHER INFORMATION

 

Sr. No.

Check list by info agents

Available in Report (Yes/No)

1

Year of establishment

Yes

2

Constitution of the entity -Incorporation details

Yes

3

Locality of the entity

Yes

4

Premises details

No

5

Buyer visit details

----------------------

6

Contact numbers

Yes

7

Name of the person contacted

Yes

8

Designation of contact person

Yes

9

Promoter’s background

Yes

10

Date of Birth of Proprietor / Partners / Directors

Yes

11

Pan Card No. of Proprietor / Partners

No

12

Voter Id Card No. of Proprietor / Partners

No

13

Type of business

Yes

14

Line of Business

Yes

15

Export/import details (if applicable)

No

16

No. of employees

No

17

Details of sister concerns

Yes

18

Major suppliers

No

19

Major customers

No

20

Banking Details

Yes

21

Banking facility details

Yes

22

Conduct of the banking account

----------------------

23

Financials, if provided

Yes

24

Capital in the business

Yes

25

Last accounts filed at ROC, if applicable

Yes

26

Turnover of firm for last three years

Yes

27

Reasons for variation <> 20%

----------------------

28

Estimation for coming financial year

No

29

Profitability for last three years

Yes

30

Major shareholders, if available

Yes

31

External Agency Rating, if available

Yes

32

Litigations that the firm/promoter involved in

Yes

33

Market information

----------------------

34

Payments terms

No

35

Negative Reporting by Auditors in the Annual Report

No

 

 

LITIGATION DETAILS

 

LITIGATION DETAILS

Bench:- Bombay

Presentation Date : 02.12.2013

Stamp

No. :

WPST/33240/2013

Failing Date:-

02.12.2013

Petitioner:-

COMMSSIONER OF CENTRAL EXCISE

Respondent:-

MACLEODS PHARMACEUTICALS LIMITED

Petn. Adv:-

A S RAO (I257)

District:-

MUMBAI

Bench:-

DIVISION

Status:-

Pre-Admission

Last Date:-

09.12.2013

Last Coram:-

 

REGISTRAR (JUDICIAL)

 

 

Act. :

Bombay University Act

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

UNSECURED LOAN

(Rs. In Million)

Particulars

As on

31.03.2014

As on

31.03.2013

LONG TERM BORROWING

 

 

Deferred sales tax loan

19.508

19.507

SHORT TERM BORROWING

 

 

Loans and advances from related parties

6.345

6.209

Total

25.853

25.716

 

 

INDEX OF CHARGES

 

S. No.

Charge ID

Date of Charge Creation/Modification

Charge amount secured

Charge Holder

Address

Service Request Number (SRN)

1

10449202

19/09/2013

15,460,000.00

ICICI BANK LIMITED

1st Floor, GANESH DARSHAN BUILDING, L. T. ROAD, OPPOSITE SHRI SAGAR HOTEL, BORIVALI WEST - 400092, Maharashtra, INDIA

B85072510

2

10449114

19/09/2013

17,850,000.00

ICICI BANK LIMITED

1st Floor, GANESH DARSHAN BUILDING, L. T. ROAD, OPPOSITE SHRI SAGAR HOTEL, BORIVALI WEST - 400092, Maharashtra, INDIA

B85015006

3

10449057

19/09/2013

22,160,000.00

ICICI BANK LIMITED

1st Floor, GANESH DARSHAN BUILDING, L. T. ROAD, OPPOSITE SHRI SAGAR HOTEL, BORIVALI WEST - 400092, Maharashtra, INDIA

B84988856

4

10449059

19/09/2013

22,160,000.00

ICICI BANK LIMITED

1st Floor, GANESH DARSHAN BUILDING, L. T. ROAD, OPPOSITE SHRI SAGAR HOTEL, BORIVALI WEST - 400092, Maharashtra, INDIA

B84990639

 

* Date of charge modification

 

 

GENERAL INFORMATION

 

Subject is a closely held Public Company domiciled in India and incorporated under the provisions of the Companies Act, 1956. The Company is engaged in the business of pharmaceutical and related activities, including research.

 

OPERATING RESULTS

 

The Sales and other income is Rs. 28964.590 million for the year, higher by 19.39% over Rs. 24259.900 million reported in the year 2012-13. The Net profit before tax amounted to Rs.5780.010 million against Rs. 4623.150 million during last year and the profit after tax is Rs.4438.300 million which was Rs. 3707.500 million during the last year.

 

 

FIXED ASSETS

 

  • Land
  • Buildings
  • Office building
  • Plant and equipment
  • Furniture and fixtures
  • Motor vehicles
  • Computer equipment’s

CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration:

No records exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration:

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime:

            Charges or conviction registered against subject:                                                                       None

 

5]         Records on Violation of Anti-Corruption Laws:

            Charges or investigation registered against subject:                                                        None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards:

            Charges or investigation registered against subject:                                                        None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government:

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package:

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report:

            No press reports / filings exists on the subject.

 


 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.66.50

UK Pound

1

Rs.101.99

Euro

1

Rs.75.02

 

 

INFORMATION DETAILS

 

Information Gathered by :

DIP

 

 

Analysis Done by :

DIV

 

 

Report Prepared by :

PNM


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

7

PAID-UP CAPITAL

1~10

7

OPERATING SCALE

1~10

8

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

8

--PROFITABILITY 

1~10

8

--LIQUIDITY

1~10

7

--LEVERAGE

1~10

7

--RESERVES

1~10

8

--CREDIT LINES

1~10

7

--MARGINS

-5~5

---

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

YES

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

NO

--AFFILIATION

YES/NO

YES

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

DEFAULTER

 

 

--RBI

YES/NO

NO

--EPF

YES/NO

NO

TOTAL

 

67

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.